CliffBio
small molecule

ONYDA XR

CLONIDINE HYDROCHLORIDE

Loss of exclusivityJuly 2041latest FDA-listed patent expiry
CompanyTris. →See this company's full patent-cliff portfolio

Drug detail

Brand nameONYDA XR
Active ingredientCLONIDINE HYDROCHLORIDE
Strength0.1MG/ML
Dosage formSUSPENSION, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2024
Marketing statusRX

Listed patents

PatentExpiresType
11918689July 2041product
12576032July 2041use U-2357
8062667March 2029product

More from Tris.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ONYDA XR patent cliff — loss of exclusivity July 2041 | CliffBio